Skip to main content
. 2018 Jul 24;41(12):1343–1353. doi: 10.1007/s40264-018-0698-3

Fig. 1.

Fig. 1

Proportion of incident adverse events in initial 24 months of second-line ART among HIV-1 infected patients in South Africa